Nika Mohannak

Nika Mohannak

Auto-generated profile, based on publicly available information

Nika Mohannak

School of Medicine, The University of Notre Dame, Fremantle, Western Australia 6160, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2014 in Nature Communications
Verified
Journal Article
Closed access
PDF file
PLPei Ching Low
Pei Ching Low
SMSilvia Manzanero
Silvia Manzanero
NMNika Mohannak
Nika Mohannak
VNVinod K. Narayana
Vinod K. Narayana
TNTam H. Nguyen
Tam H. Nguyen
FMFrederic Andre Meunier
Frederic Andre Meunier

1 December 2019 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
NMNika Mohannak
Nika Mohannak
GPGemma Pattison
Gemma Pattison
KHKathryn Hird
Kathryn Hird
MNMerrilee Needham
Merrilee Needham
Dysphagia in inclusion body myositis (IBM) is common and associated with increased mortality and morbidity due to aspiration pneumonia, malnutrition and dehydration. There is currently no consensus on treatment of dysphagia in IBM and outcomes are variable depending on timing of intervention, patient preference and available expertise. There is a paucity of research exploring the pathophysiology of dysphagia in IBM and appropriate investigations. Increased knowledge of the aetiopathogenesis is likely to change the approach to treatment as well as improve the quality of life for patients. This review explores the epidemiology and pathophysiology of dysphagia in IBM and the currently available treatment strategies.

30 July 2019 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
RMRamón Martínez-Mármol
Ramón Martínez-Mármol
NMNika Mohannak
Nika Mohannak
LQLei Qian
Lei Qian
TWTong Wang
Tong Wang
RGRachel S. Gormal
Rachel S. Gormal
FMFrederic Andre Meunier
Frederic Andre Meunier
Alzheimer's disease (AD) is associated with the cleavage of the amyloid precursor protein (APP) to produce the toxic amyloid-β (Aβ) peptide. Accumulation of Aβ, together with the concomitant inflammatory response, ultimately leads to neuronal death and cognitive decline. Despite AD progression being underpinned by both neuronal and immunological components, therapeutic strategies based on dual targeting of these systems remains unexplored. Here, we report that inactivation of the p110δ isoform of phosphoinositide 3-kinase (PI3K) reduces anterograde axonal trafficking of APP in hippocampal neurons and dampens secretion of the inflammatory cytokine tumor necrosis factor-alpha by microglial cells in the familial AD APPswe/PS1ΔE9(APP/PS1) mouse model. Moreover, APP/PS1 mice with kinase-inactive PI3Kδ (δD910A) had reduced Aβ peptides levels and plaques in the brain and an abrogated inflammatory response compared with APP/PS1 littermates. Mechanistic investigations reveal that PI3Kδ inhibition decreases the axonal transport of APP by eliciting the formation of highly elongated tubular-shaped APP-containing carriers, reducing the levels of secreted Aβ peptide. Importantly, APP/PS1/δD910Amice exhibited no spatial learning or memory deficits. Our data highlight inhibition of PI3Kδ as a new approach to protect against AD pathology due to its dual action of dampening microglial-dependent neuroinflammation and reducing plaque burden by inhibition of neuronal APP trafficking and processing.SIGNIFICANCE STATEMENTDuring Alzheimer's disease (AD), the accumulation of the toxic amyloid-β (Aβ) peptide in plaques is associated with a chronic excessive inflammatory response. Uncovering new drug targets that simultaneously reduce both Aβ plaque load and neuroinflammation holds therapeutic promise. Using a combination of genetic and pharmacological approaches, we found that the p110δ isoform of phosphoinositide 3-kinase (PI3K) is involved in anterograde trafficking of the amyloid precursor protein in neurons and in the secretion of tumor necrosis factor-alpha from microglial cells. Genetic inactivation of PI3Kδ reduces Aβ plaque deposition and abrogates the inflammatory response, resulting in a complete rescue of the life span and spatial memory performance. We conclude that inhibiting PI3Kδ represents a novel therapeutic approach to ameliorate AD pathology by dampening plaque accumulation and microglial-dependent neuroinflammation.

1 April 2020 in Neuromuscular Disorders
Verified
Journal Article
Closed access
NMNika Mohannak
Nika Mohannak
GPGemma Pattison
Gemma Pattison
BRBronwyn Radich
Bronwyn Radich
KHKathryn Hird
Kathryn Hird
EGErin Godecke
Erin Godecke
MNMerrilee Needham
Merrilee Needham